GleamWall
中文EN

AZR Azora Therapeutics, Inc. (DE)

Pharmaceutical Preparations · Nasdaq · SEC CIK 1513525 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,397.4%
TTM EPS YoY76.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-855.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.4%
Debt / equity—
Current ratio4.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.13x
Accruals ratio-742.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.77M$440,000$432,530$619,396$521,000$732,000$746,891$730,793
SG&A expense$5.76M$5.40M$1.57M$1.27M$1.24M$1.15M$1.52M$1.21M
Operating income-$7.53M-$52.02M-$2.00M-$1.89M-$1.76M-$1.88M-$2.27M-$1.94M
Pretax income———————-$2.07M
Net income-$64.56M-$51.99M-$2.02M-$2.00M-$1.79M-$1.96M-$2.23M-$2.07M
EPS (basic)-4.52-11.25-1.48—-2.02-4.61-8.52—
EPS (diluted)-4.52-11.25-1.48—-2.02-4.61-8.52—
Weighted avg. shares (diluted)14.30M4.62M1.37M—886,852424,908261,590—
Balance sheet
Cash & equivalents$22.00M$28.71M$4.58M$5.88M$4.61M$5.92M$2.37M$3.75M
Current assets$22.38M$28.84M$4.80M$6.18M$5.01M$6.08M$2.63M$4.06M
Intangibles$3,000$3,000$2,643$3,000$2,925$3,066$3,207$3,348
Total assets$22.53M$29.09M$5.23M$6.67M$5.66M$6.80M$3.45M$5.04M
Current liabilities$5.06M$5.12M$1.51M$1.40M$1.15M$1.21M$1.32M$975,858
Total liabilities$5.06M$28.93M$1.51M$1.40M$1.15M$1.21M$1.32M$975,858
Shareholders' equity-$21.06M-$38.38M$3.72M$5.28M$4.50M$5.59M$2.13M$4.07M
Shares outstanding2.63M2.63M1.51M1.11M23.84M21.53M6.65M258,826
Cash flow statement
Operating cash flow-$6.63M-$6.36M-$1.61M-$1.32M-$1.83M-$1.75M-$1.59M-$1.45M
Investing cash flow$0——$0$0$0$150,000—
Financing cash flow-$35,000$25.21M$315,284$2.60M$525,000$5.30M$50,648$0
Stock-based compensation$958,000$137,000$147,900$168,036$147,000$124,000$236,731$180,202

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.